Navigating the FDA's Final Interim Policy on Compounding with Bulk Drug Substances: A Guide for 503A Pharmacies and 503B Outsourcing Facilities Buchanan Ingersoll & Rooney PC Is BPC 157 Banned? Oral vs. Injectable Forms Explained FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of BULK DRUG SUBSTANCES AND FDA EVALUATION FDA Proposes to Exclude GLP 1s From 503B Bulk List Drug Topics